||Anticipated Ship Date
||Ranbaxy will have a license to sell generic version Caduet in the U.S. effective November 30, 2011,
||Watson can start selling its version on May 1. Johnson & Johnson will supply Watson with the drug and receive a share of net sales until the deal ends in 2014.
||Mylan settled, can market before the patent expires
||Teva has been granted final approval and first-to-file status for Levofloxacin 750mg.
||Ranbaxy will have a license to sell generic version Lipitor in the U.S. effective November 30, 2011. Ranbaxy 180 day exclusive. Watson will have the AG
||Under the terms of the settlement, Barr will be able to market the ANDA product under license from Sanofi-Aventis as early as June 15, 2011
||end of March
||Hi-Tech has final approval and is planning to lauch then end of March
||IMPAX Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic versions of SOLODYN(R) (minocycline HCI) 45mg, 90mg and 135mg Extended-release Tablets. Medicis markets SOLODYN(R) for the treatment of moderate-to-severe acne. As previously announced on December 1, 2008, IMPAX and Medicis entered into a Settlement and License Agreement, under which IMPAX has a license to market its generic versions of SOLODYN(R) 45mg, 90mg and 135mg through Global Pharmaceuticals, IMPAX’s generic division, under the SOLODYN(R) intellectual property rights belonging to Medicis, no later than November 2011. Medicis Pharmaceutical Corp. said it settled a lawsuit again Sandoz, Sandoz will not ship any more of its version of the drug until November 2011
||The licensing agreement paves the way for Teva to launch a generic version no sooner than March 28, 2011. Under certain unspecified circumstances, Teva might not receive such rights until July 1, 2012, Abbott said in a U.S. securities filing.
||Apotex, Aurobindo, Invagen, Mylan, Sun, Teva, Torrent and Wockhardt have tentative approval
||Teva, Mylan and Sandoz have tentative approval